Engineered Serendipity
Two electrical engineers took a fresh approach to drug discovery, merging semiconductors with cellular biology.
Harvard faculty are preeminent scholars and prolific inventors. In OTD, we also understand that some academic innovations need a boost to succeed commercially.
OTD’s pioneering technology accelerator programs—the Blavatnik Biomedical Accelerator and the Physical Sciences & Engineering Accelerator—help bridge the development gap, providing focused funding and resources to validate and de-risk promising technologies for successful partnering.
What ultimately makes it all work? Passionate people.
Our wide network of venture capitalists and entrepreneurs—many of whom are Harvard alumni—give generously of their time and expertise, leading and investing in new startup companies, engaging with labs as Entrepreneurs in Residence or Experts in Residence, serving on our accelerator advisory committees, speaking at OTD events, and making valuable connections throughout Cambridge and Boston.
Two electrical engineers took a fresh approach to drug discovery, merging semiconductors with cellular biology.
Metalenz has won several 3D depth sensing designs for its metasurface optics with leading OEMs in Asia. First commercial end-product shipments from OEMs begin Q3’23.
A new startup, Quino Energy, aims to bring to market a grid-scale energy storage solution developed by Harvard researchers to facilitate more widespread adoption of renewable energy sources.
Keep in touch with news and partnering opportunities from Harvard’s Office of Technology Development.